Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02282163 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
A Phase 3 study, sponsored by Bracco Diagnostics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT02282163 is a Phase 3 study that was terminated before completion, run by Bracco Diagnostics. The registered enrollment target is 13 participants.
The verdict
NCT02282163, a Phase 3 study, was terminated before completion, sponsored by Bracco Diagnostics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
Safety and Efficacy Study in pediatric subjects aged 9 to 17 years of age with suboptimal LV EBD on non-contrast 2D echocardiography. Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults.
Interventions
- DRUG sulphur hexafluoride lipid-type A microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02282163
The ClinicalTrials.gov registry entry for NCT02282163 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sulphur hexafluoride lipid-type A microspheres is the first listed.
NCT02282163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02282163 about?
NCT02282163 is a clinical study titled "Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography". Safety and Efficacy Study in pediatric subjects aged 9 to 17 years of age with suboptimal LV EBD on non-contrast 2D echocardiography. Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults.
What is the current status of trial NCT02282163?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2015-10. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02282163?
The interventions under investigation include: sulphur hexafluoride lipid-type A microspheres (DRUG).
Who is sponsoring clinical trial NCT02282163?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.